Artykuły udostępnione publicznie: - Jeremy ShefnerWięcej informacji
Niedostępne w żadnym miejscu: 10
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
SP Aggarwal, L Zinman, E Simpson, J McKinley, KE Jackson, H Pinto, ...
The Lancet Neurology 9 (5), 481-488, 2010
Upoważnienia: US National Institutes of Health
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis
ME Cudkowicz, JM Shefner, E Simpson, D Grasso, H Yu, H Zhang, A Shui, ...
Muscle & Nerve: Official Journal of the American Association of …, 2008
Upoważnienia: US National Institutes of Health
Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis
A Hannaford, N Pavey, M van den Bos, N Geevasinga, P Menon, ...
Annals of neurology 89 (5), 979-986, 2021
Upoważnienia: National Health and Medical Research Council, Australia
Electrical impedance myography correlates with standard measures of ALS severity
SB Rutkove, JB Caress, MS Cartwright, TM Burns, J Warder, WS David, ...
Muscle & nerve 49 (3), 441-443, 2014
Upoważnienia: US National Institutes of Health
Electrodiagnosis of motor neuron disease
A Duleep, J Shefner
Physical Medicine and Rehabilitation Clinics 24 (1), 139-151, 2013
Upoważnienia: US National Institutes of Health
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis
J Shefner, JM Cedarbaum, ME Cudkowicz, N Maragakis, J Lee, D Jones, ...
Amyotrophic Lateral Sclerosis 13 (5), 430-438, 2012
Upoważnienia: US National Institutes of Health
Designing clinical trials in amyotrophic lateral sclerosis
JM Shefner
Physical medicine and rehabilitation clinics of North America 19 (3), 495-508, 2008
Upoważnienia: US National Institutes of Health
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
M Benatar, T Hansen, D Rom, MA Geist, T Blaettler, W Camu, ...
The Lancet Neurology 23 (7), 687-699, 2024
Upoważnienia: Knut and Alice Wallenberg Foundation, Swedish Research Council, Motor …
Regulatory Approval in ALS; When Is a Single Study Enough?
ME Cudkowicz, JM Shefner
Annals of neurology 91 (6), 2022
Upoważnienia: US National Institutes of Health
Theme 09-Clinical Trials and Trial Design.
J Katz, T Vu, A Chiò, C McDermott, D Devos, G Gordon, M Johnston, ...
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 24, 2023
Upoważnienia: US National Institutes of Health, National Institute for Health Research, UK
Dostępne w jakimś miejscu: 69
Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis
S Paganoni, EA Macklin, S Hendrix, JD Berry, MA Elliott, S Maiser, ...
New England Journal of Medicine 383 (10), 919-930, 2020
Upoważnienia: US National Institutes of Health
A proposal for new diagnostic criteria for ALS
JM Shefner, A Al-Chalabi, MR Baker, LY Cui, M de Carvalho, A Eisen, ...
Clinical Neurophysiology 131 (8), 1975-1978, 2020
Upoważnienia: Motor Neurone Disease Association, UK, UK Medical Research Council
Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies
BT Darras, CA Chiriboga, ST Iannaccone, KJ Swoboda, J Montes, ...
Neurology 92 (21), e2492-e2506, 2019
Upoważnienia: US Department of Defense, US National Institutes of Health
Improving clinical trial outcomes in amyotrophic lateral sclerosis
MC Kiernan, S Vucic, K Talbot, CJ McDermott, O Hardiman, JM Shefner, ...
Nature Reviews Neurology 17 (2), 104-118, 2021
Upoważnienia: National Health and Medical Research Council, Australia, Motor Neurone …
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
P Kaufmann, JLP Thompson, G Levy, R Buchsbaum, J Shefner, ...
Annals of Neurology: Official Journal of the American Neurological …, 2009
Upoważnienia: US National Institutes of Health
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
ME Cudkowicz, S Titus, M Kearney, H Yu, A Sherman, D Schoenfeld, ...
The Lancet Neurology 13 (11), 1083-1091, 2014
Upoważnienia: US National Institutes of Health
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
MR Turner, R Bowser, L Bruijn, L Dupuis, A Ludolph, M McGrath, ...
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14 (sup1), 19-32, 2013
Upoważnienia: US National Institutes of Health, Motor Neurone Disease Association, UK, UK …
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
S Paganoni, S Hendrix, SP Dickson, N Knowlton, EA Macklin, JD Berry, ...
Muscle & nerve 63 (1), 31-39, 2021
Upoważnienia: US Department of Defense, US National Institutes of Health, Chan Zuckerberg …
Quantifying disease progression in amyotrophic lateral sclerosis
NG Simon, MR Turner, S Vucic, A Al‐Chalabi, J Shefner, ...
Annals of neurology 76 (5), 643-657, 2014
Upoważnienia: National Health and Medical Research Council, Australia, Motor Neurone …
Multipoint incremental motor unit number estimation as an outcome measure in ALS
JM Shefner, ML Watson, L Simionescu, JB Caress, TM Burns, ...
Neurology 77 (3), 235-241, 2011
Upoważnienia: US National Institutes of Health
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy